Video

Dr John Eikelboom on the Surprising Results of the COMPASS Trial

John Eikelboom, MD, of McMaster University discusses the 3 outcomes of the COMPASS trial that address the main concerns of patients.

John Eikelboom, MD, of McMaster University discusses the 3 outcomes of the COMPASS trial that address the main concerns of patients.

Transcript (slightly modified)

What specific data set from the COMPASS trial were you most surprised with?

The COMPASS trial results are, of course, exciting, but also some outstanding results, some results that really heighten the imagination. What are the 3 outcomes that my patient says “I just absolutely do not want these outcomes”? Well the first that comes to mind is stroke—42% risk reduction in stroke. Unexpected and I think real, although, there is a play of chance and maybe it was a little bit bigger of a treatment effect than we’d anticipated, but who could imagine that we would reduce the risk of ischemic stroke by almost 50%.

The second outcome that my patients fear is an amputation. I don’t think there’s anybody in the world who does not fear the prospect of amputation. In the COMPASS trial, we saw a reduction by half, by more than half, in the need for amputation.

The third outcome I think my patients don’t want is, by and large, they don’t want to die. It’s very hard to show mortality benefit in any antithrombotic population during long term treatment, but plucking these people of the street with chronic, stable cardiovascular disease and mortality reduction, I would say they are my 3 highlights.

Related Videos
Marla Black Morgan, MD, Phoebe Neurology Associates
Christine Funke, MD
5 experts are featured in this series
5 experts are featured in this series
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
1 expert in this video
1 expert in this video
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo